Investigation of Efficacy and Acquired Resistance for EGFR-TKI plus Bevacizumab as First-Line Treatment in Patients with EGFR Sensitive Mutant Non-Small Cell Lung Cancer in a Real World Population

Lung cancer is the leading cause of cancer-related deaths worldwide [1]. A significant proportion of patients with non-small cell lung cancer (NSCLC), particularly those with adenocarcinoma histology, carry EGFR mutations, with about 15% in Caucasian adenocarcinoma and 50% in Asian adenocarcinoma are EGFR mutants [1 –3]. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been established as the standard therapy in the first-line treatment of advanced NSCLC with EGFR mutations.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

CONCLUSIONS: We strictly determined prognostic genes of NSCLC, which would contribute to its carcinogenesis investigation and therapeutic methods improvement. PMID: 32083573 [PubMed - as supplied by publisher]
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
Lung adenocarcinoma (LUAD) is a common histological type of non-small cell lung cancer (NSCLC), accounting for nearly 40% of all lung cancers [1]. Current research has identified several LUAD-specific oncoproteins with differential expression of wildtype or mutant forms, which includes the REarranged during Transfection (RET) receptor tyrosine kinase (RTK). The expression and activation of RET has been implicated in multiple cancers, including lung [2,3]. RET is expressed at low levels in normal lung tissues, however RET gene rearrangements give rise to chimeric proteins with constitutive kinase activity that drive tumouri...
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
AbstractAnti ‐programmed cell death 1 (PD‐1) and its ligand (PD‐L1) has emerged as a novel immunotherapy for non‐small cell lung cancer (NSCLC). However, the proportion of patients who may benefit from immunotherapy is limited and the factors sensitive or resistant to immunotherapy are not completely cle ar. Therefore, to identify reliable biomarkers as predictors of clinical response and resistance to anti‐PD‐1/PD‐L1 therapies have become increasingly important. Here, we report a case of a patient with bone metastatic NSCLC, who achieved a pathologic complete response after preoperative pembr olizumab treatm...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: CASE REPORT Source Type: research
Despite the increase of therapeutic options available in clinical setting, non-small cell lung cancer (NSCLC) still remains the leading cause of cancer-related death in both sexes worldwide, representing over 85% of all lung cancers.[1] The clinical knowledge of the epidermal growth factor receptor (EGFR) molecular status, emerging over a decade ago, has led to a dramatic shift in the treatment paradigm of metastatic NSCLC. The prevalence of EGFR mutations ranges from 10% to 15% in Caucasian patients [2] and up to 50% in East-Asian patients, [3] mainly but not only with adenocarcinoma histology, female gender and quite pec...
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research
Conclusion: The miR-1323 promoted LUAD migration through inhibiting Cbl-b expression. High miR-1323 expression predicted poor prognosis in LUAD patients.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Cancer diagnosis should always be considered in patients with unprovoked thrombosis and, if NSCLC is diagnosed, genetic alterations should be always sought after. A possible relation between venous thromboembolism and oncogenic drivers, particularly for ALK translocations, has been hypothesized. Similarly to ALK-positive NSCLC, ROS1 rearranged disease has been associated with an increased thromboembolic risk. Further studies are needed to better evaluate this relation and to evaluate the potential benefit of a prophylactic anticoagulating treatment in this subset of patients. PMID: 32066344 [PubMed - as supplied by publisher]
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research
Abstract The purpose of the present study was to evaluate the clinical profiles and treatment outcomes of patients with lung cancer admitted to the Medical Psychiatric Unit (MPU), which is built for patients with physical and severe psychiatric disorders. All medical records of patients with lung cancer admitted to the MPU of Tachikawa hospital were reviewed. The clinical outcomes of these patients were retrospectively evaluated between January 2010 and December 2016. A total of 24 patients in the MPU were histologically or cytologically diagnosed with primary lung cancer. Of these, 20 patients had schizophrenia, ...
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Mol Clin Oncol Source Type: research
Advanced non-small cell lung cancer (NSCLC) is a devastating disease that is incurable and associated with poor outcomes worldwide [1]. Targeted therapies with predictive biomarkers have changed the health care strategy for metastatic NSCLC patients [2]. An anaplastic lymphoma kinase (ALK) gene rearrangement is a distinct driving mutation that occurs in as many as 8% of patients with NSCLC. Of note, different fusion partners can influence the response to ALK inhibition in patients with NSCLC [3].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
In this study, we evaluated the efficacy of anlotinib as third ‐ or further‐line treatment for patient with different histological types of NSCLC. In the ALTER0303 trial, 336 patients had the histological subtype of adenocarcinoma (ACC), 86 patients had the histological subtype of squamous cell carcinoma (SCC), and 15 patients had another subtype. Our findi ngs suggest that anlotinib significantly improves PFS and OS in ACC patients and has a tendency to prolong survival in SCC patients. AbstractBackgroundAnlotinib showed significant survival benefits in advanced non ‐small cell lung cancer (NSCLC) patients as a thir...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Authors: Pu J, Shen J, Zhong Z, Yanling M, Gao J Abstract Paclitaxel (PTX), a tubulin-binding agent, is widely used and has shown good efficacy in the initial period of treatment for non-small cell lung cancer (NSCLC). However, the relatively rapid acquisition of resistance to PTX treatments that is observed in virtually all cases significantly limits its utility and remains a substantial challenge to the clinical management of NSCLC. The aim of this study was to identify candidate genes and mechanisms that might mediate acquired paclitaxel resistance. In this work, we established paclitaxel-resistant cells (A549-T...
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
More News: Adenocarcinoma | Avastin | Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer